Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).
Jenne
L
L
Sauter
B
B
Thumann
P
P
Hertl
M
M
Schuler
G
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab; D008297:Male; D009363:Neoplasm Proteins / Q000627:therapeutic use*; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D047889:Receptors, Tumor Necrosis Factor, Type II; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors
D000911:Antibodies, Monoclonal; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab